• No results found

[PDF] Top 20 Patient perceptions of multiple sclerosis and its treatment

Has 10000 "Patient perceptions of multiple sclerosis and its treatment" found on our website. Below are the top 20 most common "Patient perceptions of multiple sclerosis and its treatment".

Patient perceptions of multiple sclerosis and its treatment

Patient perceptions of multiple sclerosis and its treatment

... Of the 175 neurologists who had agreed to take part, 47% were practicing in a hospital setting only, 28% were in community practice, and 25% worked in both settings. Of these, 84 neurologists (48.0%) recruited at least ... See full document

11

An update of teriflunomide for treatment of multiple sclerosis

An update of teriflunomide for treatment of multiple sclerosis

... Teriflunomide Multiple Sclerosis Oral (TEMSO) trial was the first Phase III clinical trial assessing the efficacy of teriflunomide in MS ...study treatment period was 108 ... See full document

14

Natalizumab in the treatment of multiple sclerosis

Natalizumab in the treatment of multiple sclerosis

... relapsing multiple sclerosis ...but its use was halted a few months after its induction after several cases of progressive multifocal leukoencephalopathy (PML), a fatal demyelinating disease ... See full document

10

Profile of oral laquinimod and its potential in the treatment of multiple sclerosis

Profile of oral laquinimod and its potential in the treatment of multiple sclerosis

... gressive multiple sclerosis ...Score, Multiple Scle- rosis Functional Composite, Quality of Life-36, and safety ...point treatment was ... See full document

8

Spotlight on daclizumab: its potential in the treatment of multiple sclerosis

Spotlight on daclizumab: its potential in the treatment of multiple sclerosis

... Abstract: Multiple sclerosis (MS) is a chronic inflammatory-demyelinating disease of the central nervous system of a putative autoimmune ...the treatment of relapsing forms of ... See full document

15

An update on the use of natalizumab in the treatment of multiple sclerosis: appropriate patient selection and special considerations

An update on the use of natalizumab in the treatment of multiple sclerosis: appropriate patient selection and special considerations

... of multiple sclerosis (MS) therapeutics, choosing the appropriate treatment for an individual patient is becoming increasingly ...life. Its use is limited by the risk of progressive ... See full document

10

Alemtuzumab in the treatment of multiple sclerosis: patient selection and special considerations

Alemtuzumab in the treatment of multiple sclerosis: patient selection and special considerations

... Multiple sclerosis (MS) is the most common chronic inflammatory disease of the cen- tral nervous system (CNS) in western countries and the leading cause of nontraumatic neurological disability in young ... See full document

8

Alemtuzumab for the treatment of multiple sclerosis

Alemtuzumab for the treatment of multiple sclerosis

... the treatment of active, relapsing multiple sclerosis ...unclear, treatment results in a marked reduction in annualized relapse rates, slowing of disability progression compared with an active ... See full document

10

Enhanced patient support services improve patient persistence with multiple sclerosis treatment

Enhanced patient support services improve patient persistence with multiple sclerosis treatment

... relapsing multiple sclerosis (MS). While early treatment with disease-modifying drugs may maximize therapeutic benefit, patients with low adherence or long treatment gaps are at increased risk ... See full document

7

Emerging therapies for treatment of multiple sclerosis

Emerging therapies for treatment of multiple sclerosis

... Abstract: In the last decade, a new armamentarium of immune-based therapies have been developed and tested in patients with multiple sclerosis. Some of these therapies are showing a high level of efficacy, ... See full document

7

Review of teriflunomide and its potential in the treatment of multiple sclerosis

Review of teriflunomide and its potential in the treatment of multiple sclerosis

... in multiple sclerosis (MS) patients who received treatment with upcoming disease-modifying immunosuppressant drugs with a highly specific mode of action such as natalizumab, rituximab, or ... See full document

8

Teriflunomide for the treatment of relapsing–remitting multiple sclerosis: patient preference and adherence

Teriflunomide for the treatment of relapsing–remitting multiple sclerosis: patient preference and adherence

... Abstract: Multiple sclerosis (MS), a chronic demyelinating neuroinflammatory disease of the central nervous system, is the most common neurological disorder leading to disability in young ...eleven ... See full document

10

Patient preferences for treatment of multiple sclerosis with disease-modifying therapies: a discrete choice experiment

Patient preferences for treatment of multiple sclerosis with disease-modifying therapies: a discrete choice experiment

... Statistical analyses of patient characteristics were performed using SPSS 20.0 (IBM Corporation, Armonk, NY, USA). Pos- sible explanatory variables for the preferences were analyzed by consecutively evaluating the ... See full document

12

Alemtuzumab in the treatment of multiple sclerosis

Alemtuzumab in the treatment of multiple sclerosis

... were relapse rate and time to 6-month sustained accumula- tion of disability (measured using the Expanded Disability Status Scale [EDSS]) 24 months after the first treatment administration. The two studies ran ... See full document

9

Diagnosis and treatment of multiple sclerosis in pediatric and adolescent patients: current status and future therapies

Diagnosis and treatment of multiple sclerosis in pediatric and adolescent patients: current status and future therapies

... of treatment failure is challenging; it is the one that has undergone significant debate among practitioners treating adult-onset ...given treatment is necessary prior to deeming that treatment to be ... See full document

11

Recent advances in the treatment of multiple sclerosis

Recent advances in the treatment of multiple sclerosis

... Abstract: Multiple sclerosis (MS) is a chronic inflammatory, immune-mediated, demyelinating, neurodegenerative disorder of the central nervous system. Despite the lack of an etiologic factor, it has been ... See full document

7

Multiple sclerosis: Immunopathology and treatment update

Multiple sclerosis: Immunopathology and treatment update

... In the early 1900s, only a few cases of multiple sclerosis (MS) were reported, which quickly became a common occurrence for admission to neurological wards. Today, MS accounts over 2.5 million affected ... See full document

27

Treatment of refractory epilepsy with natalizumab in a patient with multiple sclerosis. Case report

Treatment of refractory epilepsy with natalizumab in a patient with multiple sclerosis. Case report

... tuberous sclerosis complex ...successful treatment of epilepsy with natalizumab in a patient with ...GA treatment whereas seizure frequency, duration and severity highly ... See full document

8

Patient expectations and experiences of multiple sclerosis interferon ß-1a treatment: a longitudinal, observational study in routine UK clinical practice

Patient expectations and experiences of multiple sclerosis interferon ß-1a treatment: a longitudinal, observational study in routine UK clinical practice

... Home delivery of sc IFN β -1a therapy is a good example of the complementary roles of the NHS MS center team and the homecare delivery company when collaborating to maximize patients’ adherence to therapy. The results of ... See full document

9

Treatment of Multiple Sclerosis

Treatment of Multiple Sclerosis

... [28] Sanofi-Aventis 2016 An International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment with[r] ... See full document

9

Show all 10000 documents...